U.K. House Of Lords Declares Amgen's Erythropoietin Patent Invalid

Law360, New York (October 21, 2004, 12:00 AM EDT) -- In yet another twist in one of the most dramatic weeks of the seven-year patent battle between biotech rivals Amgen Inc. and Transkaryotic Therapeutics Inc., the U.K.’s House of Lords has stripped Amgen of the patent covering its blockbuster anemia treatment Erythropoietin (EPO).

Dealing TKT some welcome relief after a setback in the U.S. earlier in the week, the U.K.'s highest court upheld on Thursday the Court of Appeal's decision that TKT and its partner, French drug maker Sanofi-Aventis, did not infringe Amgen's patent and reversed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.